MedTrace Logo

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators

NCT03405090 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-03

No results posted yet for this study

Summary

Activity-related breathlessness (dyspnea) is the dominant symptom and persists despite optimal medical care in as many as 50% of patients with advanced chronic obstructive pulmonary disease (COPD). The objective of this project is to determine the underlying mechanisms of the activity-related breathlessness in patients with advanced COPD. To study the different pathways involved in causing breathlessness, we will compare the effects of two treatments, opiates with oxygen versus bronchodilators, which relieve breathlessness in different ways.

Conditions

Interventions

DRUG

Fentanyl Citrate

100 mcg fentanyl citrate will be inhaled via nebulizer

DRUG

Combivent

0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer

Sponsors & Collaborators

  • Ontario Lung Association

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Dr. Denis O'Donnell

    lead OTHER

Principal Investigators

  • Denis E O'Donnell, MD, FRCPC · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2022-03-21
Completion
2023-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03405090 on ClinicalTrials.gov